We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
- Authors
Jung-Yun Lee; Young Shin Chung; Kiyong Na; Hye Min Kim; Park, Cheol Keun; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim; Hyun-Soo Kim
- Abstract
Objective: The chemotherapy response score (CRS) system based on histopathological examination has been recently proposed for tubo-ovarian high-grade serous carcinoma (HGSC) to assess response to neoadjuvant chemotherapy (NAC). This study was aimed at validating the CRS system in an external cohort of tubo-ovarian HGSC patients. Methods: This study included 110 tubo-ovarian HGSC patients who underwent NAC followed by interval debulking surgery. The 3-tiered CRS of the omental and adnexal tissue sections was determined by 3 independent pathologists. Differences in patient outcomes according to CRS were analyzed. Results: The CRS system was highly reproducible among the 3 pathologists. Fleiss' kappa value and Kendall's coefficient of concordance for the omental CRS were 0.656 and 0.669, respectively. The omental CRS significantly predicted progression-free survival (PFS). The median PFS of patients whose tumors exhibited the omental CRS 1-2 (15 months) was significantly shorter than that of patients with an omental CRS of 3 (19 months; p=0.016). In addition, after adjusting for age, stage, and debulking status, the omental CRS was an independent prognostic factor for PFS of tubo-ovarian HGSC patients who were treated with NAC (adjusted hazard ratio [HR]=1.74; 95% confidence interval [CI]=1.05-2.87). Conclusion: The CRS system for assessing NAC response was a reproducible prognostic tool in our cohort. The application of the CRS system after NAC can improve survival estimation in HGSC patients.
- Subjects
CANCER chemotherapy; OVARIAN cancer treatment; CANCER in women; SPONTANEOUS cancer regression; CANCER remission
- Publication
Journal of Gynecologic Oncology, 2017, Vol 28, Issue 6, p1
- ISSN
2005-0380
- Publication type
Academic Journal
- DOI
10.3802/jgo.2017.28.e73